DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for extranodal nasal NK/T cell lymphoma — screening already-approved drugs against its 48-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleExtranodal nasal NK/T cell lymphoma maps to a 48-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for extranodal nasal nk/t cell lymphoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mitogen-activated protein kinase 1 (MAPK1) — MAPK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8AOJ · 1.12 Å · ligand 1-[(2~{S})-2-(5-methyl-3-pyridin-4-yl-1~{H}-pyrazol-4-yl)pyrrolidin-1-yl]propan-1-one (N8L). Experimental structure, not a prediction.
What the evidence adds up to
Extranodal nasal-type NK/T-cell lymphoma is a rare and aggressive malignancy, typically originating in the nasal cavity, palate, or midface, and is associated with Epstein-Barr virus. A 2012 case report describes a 40-year-old man with a palatal oronasal defect, septal perforation, and sinus involvement, treated with CHOP chemotherapy, involved-field radiotherapy, and autologous bone marrow transplantation. The authors state that early diagnosis and combined treatment may improve a poor prognosis. A 2020 report notes that primary cutaneous presentation in extranasal locations is rarer and carries a worse prognosis, with skin involvement more common in such cases.
A 2005 retrospective Korean study of 43 patients with localised disease treated with CEOP-B combination chemotherapy (cyclophosphamide, epirubicin, vincristine, bleomycin, prednisolone) reported an overall complete response rate of 44.2% (19/43) and an overall response rate of 67.4% (29/43). The median overall survival was 26.87 months (95% CI: 8.71–45.03), and median disease-free survival was 15.27 months (95% CI: 2.92–27.62). All seven patients with disease progression had their primary lesion in the nasal cavity. Upper aerodigestive tract lymphomas showed longer overall survival than nasal cavity/nasopharynx lymphomas with marginal significance (p = 0.0643). The addition of radiotherapy to chemotherapy did not show a survival benefit; median disease-free survival was 15.27 months with chemotherapy alone and 19.03 months with combined treatment. No clinical or laboratory factors predicted reduced survival except age over 60 years.
A 2012 review notes that nude mouse models and cell lines of NKTL have been established, enabling molecular genetic analysis, studies of tumour microenvironment, and investigation of targeted therapy. The authors describe these as research hotspots but provide no clinical outcome data.
What remains missing is prospective trial data comparing chemotherapy regimens, validated biomarkers to stratify patients by site of disease or genetic subtype, and funding for multi-centre studies in this rare lymphoma.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Case Reports · 2012 · 21 citations · open access
Extranodal nasal–type NK/T-cell lymphoma of the palate and paranasal sinuses
AbstractBACKGROUND: Extranodal nasal-type natural killer (NK)/T-cell lymphoma represents a rare entity, typically originating in the nasal cavity, palate or midfacial region. Signs and symptoms include non-specific rhinitis and/or sinusitis, nasal obstruction, epistaxis, facial swelling and development of deep necrotic ulceration in the midline of the palate, causing an oronasal defect. Differential diagnosis includes fungal infections, Wegener's granulomatosis, tertiary syphilis, other non-Hodgkin's lymphomas and malignant epithelial midline tumors. CASE REPORT: We present a case of a 40-year-old man complaining of headache, facial pain, nasal congestion and fever. Examination revealed a large deep necrotic ulcer in the middle of the palate, presenting as an oronasal defect. Endoscopic rhinoscopy revealed crusts in the nasal cavities, moderate perforation of the nasal septum cartilage and contraction of the middle and inferior conchae. Computer tomography showed occupation of the maxillary sinuses, ethmoidal cells and sphenoidal sinus by a hyperdense soft tissue mass. Laboratory investigation revealed increased erythrocyte sedimentation rate. A wide excision of the lesion was performed. Histopathological and immunohistochemical evaluation established the diagnosis of extranodal nasal-type NK/T-cell lymphoma. The patient was treated with CHOP chemotherapy, involved-field radiotherapy and autologous bone marrow transplantation. A removable partial denture with obturator was fabricated and inserted to relieve problems caused by the oronasal defect. CONCLUSIONS: Extranodal nasal-type NK/T-cell lymphoma is a very aggressive, rapidly progressing malignant neoplasm with a poor prognosis, which can be improved by early diagnosis and combined treatment.
JAAD Case Reports · 2020 · 4 citations · open access
Primary cutaneous nasal-type NK/T-cell lymphoma presenting as purpuric nodules on the lower leg
AbstractNasal-type extranodal natural killer (NK)/T-cell lymphoma is a rare and aggressive form of peripheral T-cell lymphoma associated with Epstein-Barr Virus and high mortality.1,2 It is rare in North America, with a higher prevalence in Asia and Central America.1 Patients with nasal-type extranodal NK/T-cell lymphoma presenting in an extranasal location represent the minority of such cases, but tend to exhibit a more advanced stage of disease with a worse prognosis.2,3 Moreover, skin involvement is significantly more common in nasal-type extranodal NK/T-cell lymphoma in extranasal locations.
Treatment Outcome of Localized Extranodal NK/T Cell Lymphoma in Nasal and Upper Aerodigestive Tract: A Single Institue Experience in Korea.
AbstractAbstract Purpose: Extranodal natural killer (NK)/T-cell lymphoma presents mostly with localized disease at diagnosis and shows predominant nasal involvement. However, the optimal treatment is not established and the role of chemotherapy as a front-line therapy is still unclear. Furthermore, treatment outcome of extranasal NK/T cell lymphoma, especially upper aerodigestive tract lymphoma has not well been documented. Thus, we performed a retrospective analysis in localized extranodal NK/T cell lymphomas occurring from nasal and upper aerodigestive tract treated with combination chemotherapy of CEOP-B as a front-line therapy. Methods: Between January 2000 and April 2005, 43 patients with newly diagnosed extranodal NK/T-cell lymphoma were treated with CEOP-B combination chemotherapy. On day 1, cyclophosphamide, epirubicin, vincristine and bleomycin were intravenously infused, and prednisolone was orally administered for 5 days. Chemotherapy was repeated with 21 days up to 6 cycles and response was assessed every two cycles. 26 patients were treated with chemotherapy alone, while radiation therapy was given sequential to chemotherapy in 17 patients. Results: 30 males and 13 females were enrolled. The median age of the patients was 40 years (range 20–74). Most patients had low international prognostic index scores (low: 31, low intermediate: 12). 29 patients had nasal cavity/nasopharynx involvement, and 14 patients had upper aerodigestive tract involvement. 14 CR including CR-u (CR: 8, CR-u: 6) and 16 PR was observed after the 2nd cycle. 4 CR-u and one CR were observed from patients with PR after the completion of chemotherapy. Thus, the overall CR rate was 44.2% (19/43) and overall response rate was 67.4% (29/43). There was no difference of response rate to chemotherapy between the lymphomas from nasal cavity/nasopharynx and from the upper aerodigestive tract. However, all the 7 patients with disease progression had their primary lesion in the nasal cavity. The median overall survival for all patients was 26.87 months (95% CI: 8.71–45.03) and the median disease-free survival is 15.27 months (95% CI: 2.92–27.62). When the two groups were classified according to the site of involvement, the upper aerodigestive tract lymphomas showed longer overall survival than the nasal cavity/nasopharynx lymphomas with marginal significance (p = 0.0643). However, there was no difference in regards to disease-free survival (p = 0.1078). The patients treated with chemotherapy alone have shown the median disease-free survival (15.27 months, 95% CI: 5.77–24.76) similar to the patients treated with chemotherapy and radiotherapy (19.03 months, 95% CI: 1.07–41.97). In the univariate and multivariate analysis, there was no clinical and laboratory factors predicting reduced survival except age (older than 60 years old). Conclusions: The frontal use of chemotherapy achieved a response rate comparable to the previous results in localized extranodal NK/T cell lymphoma, but the addition of radiation failed to show survival benefit. NK/T cell lymphomas occurring from upper aerodigestive tract showed better treatment outcomes than nasal NK/T cell lymphomas.
Recurrence 14 Years After Initial Treatment of Extranodal NK/T Cell Lymphoma, Nasal Type
AbstractExtranodal NK/T cell lymphoma, nasal type (ENKL) primarily involves the nasal cavity. Although patients might visit an otorhinolaryngologist with nasal symptoms, such as nasal obstruction and epistaxis, it would be difficult to make a diagnosis correctly. We present a case of ENKL in which the patient had been in remission after initial treatment and relapsed 14 years after treatment. The patient had a worsening of nasal symptoms before the recurrence, but on this occasion, treatment such as sinusitis was successful in alleviating the symptoms. Although recurrence of lymphoma 10 years after treatment is rare, the possibility of recurrence should always be considered in post-malignant lymphoma cases as with any malignant tumor.
Biological characteristics and molecular biology research hotspots of extranodal NK/T-cell lymphoma,nasal type
AbstractExtranodal NK/T-Cell lymphoma,nasal Type (NKTL) is an individual type in the World Health Organization (WHO) classification.The reports for NKTL are relatively uncommon since the incidence of this disease is low. In recent years, the nude mice model and cell lines of NKTL were established which built up the basis of researches in molecular biology. The investigation are carried out in molecular genetic analysis of lymphoproliferative disorders,tumor microenvironment,and target therapy and so on.We reviewed those advances and concentrated on the development of NKTL molecular biology.
Key words:
Lymphoma, extranodal NK-T-cell; Cell line; Genes; Molecular biology
Treatment progress of extranodal NK/T cell lymphoma
AbstractExtranodal NK/T cell lymphoma is a kind of disease that is associated with EB virus infection and characterized by progressive distruction and necrosis of the nasal cavity and midline facial tissues, with histological features of diffuse lymphomatous cells inflitrate and inflammatory cells as a background or angiocentric and angioinvasive inflitrate.The prognosis is poor,as it is highly aggressive and it can progress rapidly.This article mainly discusses and reviews the progress in treatment methods.
Key words:
Lymphoma, T-cell; Therapy
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
